Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

Authors

• Bernhard Reis
• Lori Jukofsky
• Gong Chen
• Giovanni Martinelli
• Hua Zhong
• W Venus So
• Michael J Dickinson
• Mark Drummond
• Sarit Assouline
• Maneja Hashemyan
• Michel Theron
• Steven Blotner
• Je-Hwan Lee
• Margaret Kasner
• Sung-Soo Yoon
• Ruediger Rueger
• Karen Seiter
• Steven A Middleton
• Kevin R Kelly
• Norbert Vey
• Karen Yee
• Gwen Nichols
• Lin-Chi Chen
• William E Pierceall

Publication/Presentation Date

5-1-2016

Volume

101

Issue

5

First Page

185

Last Page

188

ISSN

1592-8721

Published In/Presented At

Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., Theron, M., Blotner, S., Lee, J. H., Kasner, M., Yoon, S. S., Rueger, R., Seiter, K., Middleton, S. A., Kelly, K. R., Vey, N., … Pierceall, W. E. (2016). Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica, 101(5), e185–e188. https://doi.org/10.3324/haematol.2015.139717

Disciplines

Medicine and Health Sciences

PubMedID

26869629

Department(s)

Hematology-Medical Oncology Division

Document Type

Article